Key Highlights

● IceCure Medical fell about 11.5% to close near $3.11, for a market Capitalization of roughly $10.6 million, even as first-half 2026 Revenue rose 45%.

● Revenue reached about $1.8 million for the first half, up from roughly $1.25 million a year earlier, with Gross Profit of $548,000 versus $349,000.

● The net loss widened to $8.775 million from $6.952 million, with operating expenses higher across R&D, sales and marketing, and G&A.

● IceCure held about $12.0 million in cash at June 30, 2026, with roughly $8.5 million in gross proceeds raised during the half, and the active US commercial installed base grew roughly 70%.

Shares of IceCure Medical (NASDAQ: ICCM) fell about 11.5% on Tuesday, August 12, 2026, closing near $3.11, after the cryoablation medical-device company reported first-half 2026 results that showed strong revenue growth but a widening net loss. Revenue rose 45% year over year, and the company reported a roughly 70% increase in its active U.S. commercial installed base, yet spending on research, sales and administration outpaced those gains and pushed losses higher. For a micro-cap that recently executed a 1-for-30 reverse split to stay listed on Nasdaq, the deepening loss and a soft quarter overshadowed the top-line momentum, leaving the stock sharply lower.

What Happened?

On August 12, IceCure Medical released financial and operating results for the first half of 2026, the six months ended June 30. Revenue climbed 45% to about $1.8 million from roughly $1.25 million a year earlier, driven by sales of its ProSense cryoablation systems and disposable probes. Gross profit rose to $548,000 from $349,000, for a gross Margin of about 30%.

Despite that growth, the net loss widened to $8.775 million from $6.952 million in the first half of 2025. The company attributed the deeper loss to higher research and development, sales and marketing, and general and administrative expenses that outpaced the improvement in gross profit. Net loss per share was $3.17, a figure that reflects the company's low post-split share count. IceCure ended the period with about $12.0 million in cash, having raised roughly $8.5 million in gross proceeds during the half through issuances of ordinary shares, warrants and pre-funded warrants.

Why Is ICCM Stock Falling?

The decline came as investors weighed accelerating revenue against a widening loss and continued cash burn. The confirmed facts are clear: revenue grew 45%, but the net loss expanded by roughly $1.8 million year over year because operating expenses across R&D, sales and marketing, and G&A rose faster than gross profit. Reporting alongside the release also indicated the company's second-quarter results came in below analyst estimates.

For a company of this size, the market appears to be focused on the gap between a small revenue base, under $2 million for the half, and a loss approaching $9 million, which raises questions about how long the current cash position can fund operations. That is the plausible interpretation behind the sell-off; IceCure did not state that its cash is inadequate. It is also worth noting that micro-cap stocks like ICCM, especially those that have recently reverse-split, are prone to outsized swings on earnings, and a double-digit move on a day like this fits that pattern. The revenue growth and installed-base expansion are real positives, but they were not enough to offset concern about the loss trajectory.

The Numbers Investors Are Watching

- Revenue: about $1.8 million for the first half of 2026, up 45% from roughly $1.25 million a year earlier.

- Gross profit: $548,000 (versus $349,000), for a gross margin near 30%.

- Net loss: $8.775 million, widened from $6.952 million; net loss per share of $3.17.

- Operating expenses: R&D of about $4.3 million, sales and Marketing of about $2.5 million, and G&A of about $2.4 million, all higher year over year.

- Cash: about $12.0 million at June 30, 2026, with roughly $8.5 million in gross proceeds raised during the half; total Assets of about $17.7 million and shareholders' Equity of about $11.9 million.

- Installed base: roughly 70% growth in active U.S. commercial installations.

- Market snapshot: shares closed near $3.11 (down about 11.5%), for a market capitalization of roughly $10.6 million, with about 3.43 million shares outstanding and a 52-week range of about $2.12 to $42.00.

The Bigger Picture

IceCure Medical, based in Israel, develops cryoablation technology that destroys tumors by freezing them, marketed primarily through its ProSense system. Its lead commercial opportunity is minimally invasive treatment of tumors, with a particular focus on breast cancer, supported by the ongoing CHoICE post-marketing study. ProSense is cleared by the U.S. Food and Drug Administration, and the company has been building out its U.S. commercial footprint.

The stock has had a turbulent stretch. In 2026 the company enacted a 1-for-30 reverse share split to support compliance with Nasdaq's minimum bid price requirement, and it later regained compliance around late June. The wide 52-week trading range, from roughly $2 to $42 on a split-adjusted basis, underscores how volatile the shares have been and how far they sit below prior highs. Against that backdrop, the first-half report reinforced the central tension in the IceCure story: encouraging commercial traction paired with persistent losses and reliance on external financing.

What Could Happen Next?

Key catalysts ahead include progress and any data readouts from the CHoICE study for the breast cancer indication, further U.S. commercial expansion and installed-base growth, and any additional regulatory milestones for ProSense or related products. Investors will also watch the company's cash runway closely; with roughly $12 million in cash against a loss pace near $9 million per half, additional financing at some point is a realistic possibility, and any raise could be dilutive given the small share count. IceCure's next financial update, covering later 2026 periods, will be important for gauging whether revenue growth continues to accelerate and whether operating losses begin to stabilize. Nasdaq listing status and bid-price compliance remain worth monitoring as well.

Bottom Line

IceCure Medical delivered exactly the kind of top-line growth it needs, 45% revenue gains and a sharply larger U.S. installed base, but the stock fell about 11.5% because the net loss widened as spending outran gross profit and the quarter came in light. For a micro-cap with a small revenue base, a loss near $9 million and about $12 million of cash, the market's focus is squarely on the path to sustainability and the risk of further dilution. The most important things to monitor from here are the CHoICE study, commercial momentum, operating-expense discipline and the cash runway. Until losses narrow relative to revenue, the shares are likely to stay volatile despite the encouraging growth.